# Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis

> **NCT00396422** · PHASE2 · COMPLETED · sponsor: **Alza Corporation, DE, USA** · enrollment: 60 (actual)

## Conditions studied

- Chronic Small Plaque Psoriasis

## Interventions

- **DRUG:** RWJ-445380

## Key facts

- **NCT ID:** NCT00396422
- **Lead sponsor:** Alza Corporation, DE, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2011-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396422, "Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00396422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*